[go: up one dir, main page]

PE20070490A1 - Compuestos derivados de bencimidazol-2-ona sustituidos con piperidina como agonistas del receptor muscarinico m1 - Google Patents

Compuestos derivados de bencimidazol-2-ona sustituidos con piperidina como agonistas del receptor muscarinico m1

Info

Publication number
PE20070490A1
PE20070490A1 PE2006001183A PE2006001183A PE20070490A1 PE 20070490 A1 PE20070490 A1 PE 20070490A1 PE 2006001183 A PE2006001183 A PE 2006001183A PE 2006001183 A PE2006001183 A PE 2006001183A PE 20070490 A1 PE20070490 A1 PE 20070490A1
Authority
PE
Peru
Prior art keywords
ona
muscarine
benzymidazole
piperidine
receptor agonists
Prior art date
Application number
PE2006001183A
Other languages
English (en)
Inventor
Brian Budzik
David Gwyn Cooper
Ian Thomson Forbes
Vincenzo Garzya
Jian Jin
Dongchuan Shi
Paul William Smith
Graham Walker
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0519950.0A external-priority patent/GB0519950D0/en
Priority claimed from GB0602040A external-priority patent/GB0602040D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20070490A1 publication Critical patent/PE20070490A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA (I) DONDE R4 ES FLUOR; R5 ES H, HALOGENO, CN, ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO CON F O ALCOXI(C1-C6), ENTRE OTROS; R6 ES HALOGENO, CN, ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO CON F O CICLOALQUILO(C3-C6), ENTRE OTROS; Q ES H O ALQUILO(C1-C6). SON COMPUESTOS PREFERIDOS: 4-FLUORO-6-METIL-1-[1-(TETRAHIDRO-2H-PIRAN-4-IL)-4-PIPERIDINIL]-1,3-DIHIDRO-2H-BENCIMIDAZOL-2-ONA, 6-CLORO-4-FLUORO-1-[1-(TETRAHIDRO-2H-PIRAN-4-IL)-4-PIPERIDINIL]-1,3-DIHIDRO-2H-BENCIMIDAZOL-2-ONA, 4-FLUORO-6-METOXI-1-[1-(TETRAHIDRO-2H-PIRAN-4-IL)-4-PIPERIDINIL]-1,3-DIHIDRO-2H-BENCIMIDAZOL-2-ONA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON AGONISTAS DEL RECEPTOR MUSCARINICO M1 SIENDO UTILES EN EL TRATAMIENTO DE TRASTORNOS PSICOTICOS Y ALTERACIONES COGNITIVAS TAL COMO TRASTORNOS DE LA ATENCION, ORIENTACION, APRENDIZAJE, MEMORIA
PE2006001183A 2005-09-30 2006-09-28 Compuestos derivados de bencimidazol-2-ona sustituidos con piperidina como agonistas del receptor muscarinico m1 PE20070490A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0519950.0A GB0519950D0 (en) 2005-09-30 2005-09-30 Compounds
GB0602040A GB0602040D0 (en) 2006-02-01 2006-02-01 Compounds

Publications (1)

Publication Number Publication Date
PE20070490A1 true PE20070490A1 (es) 2007-05-30

Family

ID=37598231

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001183A PE20070490A1 (es) 2005-09-30 2006-09-28 Compuestos derivados de bencimidazol-2-ona sustituidos con piperidina como agonistas del receptor muscarinico m1

Country Status (24)

Country Link
US (2) US8283364B2 (es)
EP (1) EP1943230B1 (es)
JP (1) JP5209480B2 (es)
KR (2) KR20130091791A (es)
CN (1) CN101321736B (es)
AR (1) AR056103A1 (es)
AT (1) ATE492537T1 (es)
AU (1) AU2006296369B2 (es)
BR (1) BRPI0616609A2 (es)
CA (1) CA2624504C (es)
CR (1) CR9904A (es)
DE (1) DE602006019119D1 (es)
EA (1) EA016286B1 (es)
IL (1) IL190219A (es)
JO (1) JO2634B1 (es)
MA (1) MA29849B1 (es)
MY (1) MY148504A (es)
NO (1) NO20081945L (es)
NZ (1) NZ566508A (es)
PE (1) PE20070490A1 (es)
TW (1) TWI389905B (es)
UA (1) UA101299C2 (es)
WO (1) WO2007036715A2 (es)
ZA (1) ZA200802167B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2391107T3 (es) 2005-09-30 2012-11-21 Glaxo Group Limited Compuestos que tienen actividad en el receptor M1 y sus usos en medicina
WO2007036711A1 (en) 2005-09-30 2007-04-05 Glaxo Group Limited BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR
CN101321736B (zh) 2005-09-30 2012-04-04 葛兰素集团有限公司 对m1受体具有活性的化合物及其在医药中的用途
US7766829B2 (en) * 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
GB0605785D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
GB0706165D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706170D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706164D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706174D0 (en) * 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0718415D0 (en) * 2007-09-20 2007-10-31 Glaxo Group Ltd Compounds
WO2009124882A1 (en) * 2008-04-09 2009-10-15 H. Lundbeck A/S Novel piperidinyl-1,3-dihydro-benzoimidazol-2-ones as m1 agonists
GB0817982D0 (en) 2008-10-01 2008-11-05 Glaxo Group Ltd Compounds
CA2966594A1 (en) * 2014-11-03 2016-05-12 William Beaumont Hospital Method for treating underactive bladder syndrome
LT3288940T (lt) 2015-04-29 2021-05-10 Janssen Pharmaceutica Nv Azabenzimidazolai ir jų panaudojimas kaip ampa receptoriaus moduliatorių
BR112017023200A2 (pt) * 2015-04-29 2018-08-07 Janssen Pharmaceutica Nv compostos de indolona e seu uso como moduladores do receptor de ampa
EP3347011A4 (en) 2015-09-11 2019-06-19 Chase Pharmaceuticals Corporation MUSCARIN COMBINATION AND ITS USE FOR COMBATING HYPOCHOLINERGEN DISORDERS OF THE CENTRAL NERVOUS SYSTEM
CN107673994A (zh) * 2017-04-27 2018-02-09 联化科技股份有限公司 一种芳基甲烷类化合物的制备方法
CN107739342B (zh) * 2017-11-29 2020-01-10 华南理工大学 一种一步合成5-二芳氨基苯并咪唑酮衍生物的方法
CN117049938B (zh) * 2023-06-20 2024-06-14 山东轩德医药科技有限公司 一种6-溴-2,3-二氟甲苯的制备方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3161645A (en) * 1962-12-18 1964-12-15 Res Lab Dr C Janssen N V 1-(1-aroylpropyl-4-piperidyl)-2-benzimidazolinones and related compounds
US3989707A (en) * 1974-06-21 1976-11-02 Janssen Pharmaceutica N.V. Benzimidazolinone derivatives
US4292321A (en) 1979-05-24 1981-09-29 Warner-Lambert Company 1,3,8-Triazaspirodecane-4-ones, pharmaceutical compositions thereof and method of use thereof
DE3124366A1 (de) 1981-06-20 1982-12-30 Hoechst Ag, 6000 Frankfurt N-oxacyclyl-alkylpiperidin-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und deren verwendung
DE4040300A1 (de) 1990-12-17 1992-07-02 Leifeld Gmbh & Co Drueckmaschine mit wenigstens einem rollenhalter
JP3916093B2 (ja) * 1993-09-17 2007-05-16 杏林製薬株式会社 光学活性イミダゾリジノン誘導体とその製造方法
AU701127B2 (en) * 1994-10-27 1999-01-21 Merck & Co., Inc. Muscarine antagonists
US5691323A (en) * 1995-05-12 1997-11-25 Merck & Co., Inc. Muscarine antagonists
US5574044A (en) 1994-10-27 1996-11-12 Merck & Co., Inc. Muscarine antagonists
WO1997016186A1 (en) 1995-10-31 1997-05-09 Merck & Co., Inc. Muscarine agonists
US5718912A (en) 1996-10-28 1998-02-17 Merck & Co., Inc. Muscarine agonists
US5977134A (en) 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2307999A (en) * 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
AU766233B2 (en) 1999-10-13 2003-10-09 Banyu Pharmaceutical Co., Ltd. Substituted imidazolidinone derivatives
SE9904652D0 (sv) 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
AU2001234705A1 (en) 2000-02-01 2001-08-14 Cor Therapeutics, Inc. Indalone and benzimidazolone inhibitors of factor xa
JP4401076B2 (ja) 2001-04-18 2010-01-20 ユーロ−セルティーク エス．エイ． ベンズイミダゾロン化合物
CA2444595A1 (en) 2001-04-20 2002-10-31 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives
WO2004089942A2 (en) * 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
US6951849B2 (en) 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
NZ531550A (en) 2001-10-02 2006-12-22 Acadia Pharm Inc Benzimidazolidinone derivatives as muscarinic cholinergic receptors
US7244744B2 (en) 2001-11-01 2007-07-17 Icagen, Inc. Piperidines
WO2003082333A1 (fr) 2002-03-29 2003-10-09 Mitsubishi Pharma Corporation Remede contre les troubles du sommeil
AU2003245565B2 (en) 2002-06-17 2008-01-03 Banyu Pharmaceutical Co., Ltd. Ophthalmic compositions for treating ocular hypertension
US7645771B2 (en) 2002-12-13 2010-01-12 Smithkline Beecham Corp. CCR5 antagonists as therapeutic agents
JP2005102133A (ja) 2003-04-28 2005-04-14 Ricoh Co Ltd 画像形成装置及び宛先情報参照方法
MXPA06000701A (es) 2003-07-23 2006-04-11 Wyeth Corp Compuestos de sulfonildihidrobencimidazolona como ligandos de 5-hidroxitriptamina-6.
DK1664036T3 (da) 2003-09-03 2012-02-13 Pfizer Benzimidazolonforbindelser med 5-HT4-receptoragonistisk virkning
BRPI0517925A (pt) 2004-11-02 2008-10-21 Pfizer derivados de sulfonil benzimidazol
US7300947B2 (en) 2005-07-13 2007-11-27 Banyu Pharmaceutical Co., Ltd. N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives
WO2007036711A1 (en) 2005-09-30 2007-04-05 Glaxo Group Limited BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR
ES2391107T3 (es) 2005-09-30 2012-11-21 Glaxo Group Limited Compuestos que tienen actividad en el receptor M1 y sus usos en medicina
CN101321736B (zh) 2005-09-30 2012-04-04 葛兰素集团有限公司 对m1受体具有活性的化合物及其在医药中的用途
EP2068673A2 (en) 2006-09-08 2009-06-17 The Gillette Company Toothbrush with multiple bristle states
GB0706187D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706173D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706165D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706188D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706170D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706167D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706190D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706189D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706174D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706164D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds
GB0706168D0 (en) 2007-03-29 2007-05-09 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
CN101321736B (zh) 2012-04-04
JP2009512635A (ja) 2009-03-26
KR20130091791A (ko) 2013-08-19
WO2007036715A3 (en) 2007-05-18
DE602006019119D1 (de) 2011-02-03
NZ566508A (en) 2011-07-29
US20080255195A1 (en) 2008-10-16
BRPI0616609A2 (pt) 2011-06-28
AU2006296369B2 (en) 2012-12-20
CN101321736A (zh) 2008-12-10
IL190219A (en) 2012-10-31
KR101374458B1 (ko) 2014-03-17
TW200806657A (en) 2008-02-01
IL190219A0 (en) 2008-11-03
UA101299C2 (uk) 2013-03-25
AR056103A1 (es) 2007-09-19
CA2624504C (en) 2014-07-08
MA29849B1 (fr) 2008-10-03
CA2624504A1 (en) 2007-04-05
US20080058378A1 (en) 2008-03-06
EP1943230B1 (en) 2010-12-22
US8283364B2 (en) 2012-10-09
ATE492537T1 (de) 2011-01-15
ZA200802167B (en) 2009-08-26
EA016286B1 (ru) 2012-03-30
MY148504A (en) 2013-04-30
AU2006296369A1 (en) 2007-04-05
EA200801001A1 (ru) 2008-08-29
KR20080049090A (ko) 2008-06-03
TWI389905B (zh) 2013-03-21
WO2007036715A2 (en) 2007-04-05
NO20081945L (no) 2008-06-04
JO2634B1 (en) 2012-06-17
US8481566B2 (en) 2013-07-09
JP5209480B2 (ja) 2013-06-12
CR9904A (es) 2008-07-29
EP1943230A2 (en) 2008-07-16

Similar Documents

Publication Publication Date Title
PE20070490A1 (es) Compuestos derivados de bencimidazol-2-ona sustituidos con piperidina como agonistas del receptor muscarinico m1
PE20070586A1 (es) Compuestos de (4-piperidinil)-1,3-dihidro-2h-bencimidazol-2-ona sustituidos como agonistas del receptor muscarinico m1
PE20050874A1 (es) Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR065794A1 (es) Pirimidodiazepinas sustituidas
PE20080007A1 (es) Compuestos derivados de bencimidazolona que tienen actividad en el receptor m1
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20070491A1 (es) Compuestos derivados de 9-azabiciclo[3.3.1]nonano como inhibidores de la recaptacion de neurotransmisores de monoamina
PE20090437A1 (es) Antagonistas no basicos del receptor de la hormona concentradora de melanina 1 y procedimientos
PE20090237A1 (es) Derivados de sulfonamidas como inhibidores de los canales de sodio
PE20080275A1 (es) Derivados de 5h-benzo[4,5]ciclohepta[1,2]piridina como inhibidores de tirosina quinasa
PE20110875A1 (es) Derivados de isoindol como inhibidores de bace
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
PE20091724A1 (es) Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7
PE20160839A1 (es) Derivados de 4-azaindol
PE20081238A1 (es) Piperidinas sustituidas como antagonistas de hdm2
PE20091173A1 (es) Derivados de heteroarilo como antagonistas de receptor de orexina
PE20090057A1 (es) Compuestos y composiciones como moduladores de la actividad gpr119
PE20081345A1 (es) Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico
PE20110894A1 (es) Derivados de pirimidin indol para el tratamiento de cancer
PE20061150A1 (es) Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1)
PE20091090A1 (es) Derivados de piperidina como agonistas de receptores muscarinicos
PE20090482A1 (es) Derivados heterociclicos como antagonistas del receptor ccr2
PE20060361A1 (es) Compuestos heterociclicos como inhibidores de la cinesina mitotica
PE20080186A1 (es) Derivados 4,6-disustituidos de 2-metoxi-6-etilamino-pirimidina como antagonistas del receptor de prostaglandina d2

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed